Skip to main content
Fig. 4 | BMC Infectious Diseases

Fig. 4

From: Assessment of an optimized manufacturing process for inactivated quadrivalent influenza vaccine: a phase III, randomized, double-blind, safety and immunogenicity study in children and adults

Fig. 4

Solicited injection-site events in children aged 3–17 years (a) and general adverse events in children aged 3–4 years (b) and children aged 5–17 years (c) in the total vaccinated cohort. IIV4-I, quadrivalent inactivated influenza vaccine manufacturing by investigational process; IIV4, licenced quadrivalent inactivated influenza vaccine; CI, confidence interval; GI, gastrointestinal; N, number of subjects in the total vaccinated cohort who returned diary cards the per-protocol cohort

Back to article page

BMC Infectious Diseases

ISSN: 1471-2334

Contact us